Accueil / Communiqués

Communiqués

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Friday, July 19th 2019 at 12:30pm UTC FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global …

Plus »

Afya Educacional (NASDAQ:AFYA) Lists on NASDAQ

Friday, July 19th 2019 at 7:25pm UTC Brazil’s largest medical education group seeks to transform medical education NEW YORK–(BUSINESS WIRE)– Today, Afya Educacional (“Afya” or “the Company”), Brazil’s largest medical education group,1 lists on the Nasdaq under the ticker symbol NASDAQ:AFYA. The initial public offering of 13,744,210 Class A common …

Plus »

ClinOne Achieves Near Perfect Dosing Compliance During Clinical Trials

Friday, July 19th 2019 at 3:37pm UTC DENVER–(BUSINESS WIRE)– The costs and timelines to conduct clinical trials continue to increase, as does study complexity. While much of the focus in clinical trials has been on improving data quality and overall study efficiency addressing cost/timeline/complexity issues, less attention has been paid …

Plus »

Study Investigates the Ability of Continuous Noninvasive Hemoglobin Monitoring with Masimo SpHb® to Reflect Acute Hemodilution During Incremental Fluid Administration

Monday, July 22nd 2019 at 6:00am UTC NEUCHATEL, Switzerland–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilution after graded fluid administration, by …

Plus »

FDA Accepts and Files 22nd Century Group’s Modified Risk Tobacco Product Application for VLN™ Cigarettes

Friday, July 19th 2019 at 8:08pm UTC WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, announced today that the U.S. Food and Drug Administration (FDA) accepted and filed for substantive scientific review the Company’s Modified …

Plus »

Top 5 Vendors in the Global Molecular Biology Enzymes, Kits, and Reagents Market 2019-2023 | Technavio

Friday, July 19th 2019 at 2:30pm UTC LONDON–(BUSINESS WIRE)– High incidence of chronic diseases globally and the need for personalized medicine, has encouraged several technological advancements in the form of recombinant DNA that involves genetic combinations of species to treat diseases. The recombinant DNA technology increases the demand for molecular …

Plus »

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease

Monday, July 22nd 2019 at 5:00am UTC Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial …

Plus »

Top 5 Vendors in the Mercury Analyzer Market from 2019 to 2023 | Technavio

Friday, July 19th 2019 at 1:39pm UTC LONDON–(BUSINESS WIRE)– Several government bodies across the world are enforcing stringent regulations to tackle the adverse environmental effects of mercury emission. Mercury analyzers help in measuring furnace temperature and the flue gas of air pollutants. Thus, the enforcement of strict regulations to monitor …

Plus »

AVROBIO Announces Closing of Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Friday, July 19th 2019 at 8:01pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including 975,000 shares of its common stock pursuant to …

Plus »

Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma

Monday, July 22nd 2019 at 6:10am UTC Milciclib was well tolerated and no drug related deaths were reported 28 out of 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment   …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.